Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes

Current Pharmaceutical Design

Volumn 23, Issue 7, 2017, Pages 969-982

  Zabihi, Narges Amel ^a   Pirro, Matteo ^b   Johnston, Thomas P ^c   Sahebkar, Amirhossein ^d,e  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Curcumin; Dyslipidemia; Inflammation; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

CURCUMIN; FLUOROURACIL; LEPTIN; LIPID; OXALIPLATIN; TUBERCULOSTATIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOCHEMICAL ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPID OXIDATION; LIPOTOXICITY; LIVER PROTECTION; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUPPLEMENTATION; TUBERCULOSIS; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; MITOCHONDRION; PATHOLOGY;

CURCUMIN; DIETARY SUPPLEMENTS; HUMANS; MITOCHONDRIA; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS;

EID: 85020860591     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666161010115235     Document Type: Review

References (207)

1. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-30.
2. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002; 17 (Suppl 3): S377-84.
3. Argo CK, Caldwell SH. Epidemiology and natural history of nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-31.
4. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48: 1-26.
5. Rinella M, Charlton M. The globalization of non-alcoholic fatty liver disease-prevalence and impact on world health. Hepatology 2016; 64: 19-22.
6. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-30.
7. Marzuillo P, Del Giudice EM, Santoro N. Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol 2014; 6: 217-25.
8. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? 2014; 20: 9072-89.
9. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717-22.
10. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496-506.
11. Stefan N, Haring HU. The metabolically benign and malignant fatty liver. Diabetes 2011; 60: 2011-7.
12. Alkhouri N, Tamimi TA-R, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Digest Dis Sci 2010; 55: 2644-50.
13. Dam-Larsen S, Becker U, Franzmann M-B, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009; 44: 1236-43.
14. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-84.
15. Ahmed MH, Olufadi R, Byrne, Christopher D. Metabolic syndrome, diabetes and cardiovascular risk. In: Toth PP. Ed. The Year in Lipid Disorders. Oxford: GB, Clinical Publishing 2010; pp. 24-45.
16. Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008; 57: 387-92.
17. Wang CC, Lin SK, Tseng YF, et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 1411-6.
18. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-6.
19. Kozakova M, Palombo C, Paterni Eng M, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012; 55: 1406-15.
20. George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm 2008; 5: 49-59.
21. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008; 29: 939-60.
22. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008; 7: 95-6.
23. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-39.
24. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
25. Gaedeke J, Noble NA, Border WA. Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int 2005; 68: 2042-9.
26. Samuel VT, Liu Z-X, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-53.
27. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-38.
28. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-77.
29. Arner P, Langin D. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol Metab 2014; 25: 255-62.
30. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16: 1941-51.
31. Koliwad SK, Streeper RS, Monetti M, et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from dietinduced insulin resistance and inflammation. J Clin Invest 2010; 120: 756-67.
32. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American J Physiol Gastrointestinal Liver Physiol 2006; 290: G852-8.
33. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005; 33: 138-44.
34. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-23.
35. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008; 60: 311-57.
36. Senates E, Colak Y, Yesil A, et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores. Minerva Med 2012; 103: 369-76.
37. [37] Milner KL, van der Poorten D, Xu A, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1926-34.
38. Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2015; DOI: 10.1080/10408398.2015.1077195 [epub ahead of print].
39. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res 2013; 57: 1510-28.
40. Sharma O. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976; 25: 1811-2.
41. Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin J Integr Med 2015; 21: 332-8.
42. [42] Sahebkar A, Mohammadi A, Atabati A, et al. Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013; 27: 1883-8.
43. Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant–antioxidant mechanisms. Nat Prod Res 2015; 29: 491-2.
44. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29: 405-34.
45. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: Results of a randomized controlled trial. J Dietary Suppl 2015.
46. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial. Phytotherapy Res 2014; 28: 1625-31.
47. Ganjali S, Sahebkar A, Mahdipour E, et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. Scientific World J 2014; 2014: 898361.
48. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial. Phytotherapy Res 2014; 28: 1461-7.
49. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49: 580-8.
50. Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A. Shortterm curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res (Stuttg) 2015; 65: 567-73.
51. Sahebkar A. Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a metaanalysis. Phytother Res 2014; 28: 633-42.
52. Kadasa NM, Abdallah H, Afifi M, Gowayed S. Hepatoprotective effects of curcumin against diethyl nitrosamine induced hepatotoxicity in albino rats. Asian Pac J Cancer Prev 2015; 16: 103-8.
53. Mirzaei H, Naseri G, Rezaee R, et al. Curcumin: A new candidate for melanoma therapy? Int J Cancer 2016; 139: 1683-95.
54. Momtazi AA, Sahebkar A. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr Pharm Des 2016; 22 (28): 4386-97.
55. Sahebkar A. Curcumin: a natural multitarget treatment for pancreatic cancer. Integr Cancer Therap 2016; 15 (3): 333-4.
56. Iranshahi M, Sahebkar A, Hosseini S, Takasaki M, Konoshima T, Tokuda H. Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 2010; 17: 269-73.
57. Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2013; 27: 374-9.
58. Um MY, Hwang KH, Choi WH, Ahn J, Jung CH, Ha TY. Curcumin attenuates adhesion molecules and matrix metalloproteinase expression in hypercholesterolemic rabbits. Nutr Res 2014; 34: 886-93.
59. Wang Y, Li J, Zhuge L, Su D, Yang M, Tao S. Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine-and choline-deficient diet. Exp Ther Med 2014; 7: 663-8.
60. Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr 2014; 33: 406-14.
61. Fan C, Wo X, Qian Y, Yin J, Gao L. Effect of curcumin on the expression of LDL receptor in mouse macrophages. J Ethnopharmacol 2006; 105: 251-4.
62. Arafa HM. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit 2005; 11: Br228-34.
63. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat dietinduced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001; 131: 2932-5.
64. Sahebkar A. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol 2014; 114: 437-8.
65. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 2014; 11: 123.
66. Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014; 56: 47-66.
67. Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016; 111: 394-404.
68. Sankar P, Telang AG, Suresh S, et al. Immunomodulatory effects of nanocurcumin in arsenic-exposed rats. Int Immunopharmacol 2013; 17: 65-70.
69. Sahebkar A, Cicero AF, Simental-Mendia LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factoralpha levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 2016; 107: 234-42.
70. Yang Y, Wu X, Wei Z, et al. Oral curcumin has anti-arthritic efficacy through somatostatin generation via cAMP/PKA and Ca(2+)/CaMKII signaling pathways in the small intestine. Pharmacol Res 2015; 95-96: 71-81.
71. Kuncha M, Naidu VG, Sahu BD, Gadepalli SG, Sistla R. Curcumin potentiates the anti-arthritic effect of prednisolone in Freund’s complete adjuvant-induced arthritic rats. J Pharm Pharmacol 2014; 66: 133-44.
72. Kumar K, Rai AK. Proniosomal formulation of curcumin having anti-inflammatory and anti-arthritic activity in different experimental animal models. Pharmazie 2012; 67: 852-7.
73. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010; 94: e75-6.
74. Li L, Li H, Li M. Curcumin protects against cerebral ischemiareperfusion injury by activating JAK2/STAT3 signaling pathway in rats. Int J Clin Exp Med 2015; 8: 14985-91.
75. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 2013; 39: 197-208.
76. Shen LL, Jiang ML, Liu SS, et al. Curcumin improves synaptic plasticity impairment induced by HIV-1gp120 V3 loop. Neural Regen Res 2015; 10: 925-31.
77. [77] Chen K, An Y, Tie L, Pan Y, Li X. Curcumin protects neurons from glutamate-induced excitotoxicity by membrane anchored AKAP79-PKA interaction network. Evid Based Complement Alternat Med 2015; 2015: 706207.
78. Wang BF, Cui ZW, Zhong ZH, et al. Curcumin attenuates brain edema in mice with intracerebral hemorrhage through inhibition of AQP4 and AQP9 expression. Acta Pharmacol Sin 2015; 36: 939-48.
79. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-5.
80. Nishiyama T, Mae T, Kishida H, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005; 53: 959-63.
81. Sidhu GS, Singh AK, Thaloor D, et al. Enhancement of wound healing by curcumin in animals. Wound Repair Regeneration 1998; 6: 167-77.
82. Sahebkar A. The promise of curcumin–phosphatidylcholine complex for cardiometabolic diseases: more than just ‘more curcumin’. Nat Prod Res 2015; 29: 392-3.
83. Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and metaanalysis of randomized controlled trials. Pain Med 2016; 17: 1192-202.
84. Negi P, Jayaprakasha G, Jagan Mohan Rao L, Sakariah K. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 1999; 47: 4297-300.
85. Jordan W, Drew C. Curcumin--a natural herb with anti-HIV activity. J Natl Med Assoc 1996; 88: 333.
86. Kim MK, Choi GJ, Lee HS. Fungicidal property of Curcuma longa L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem 2003; 51: 1578-81.
87. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun 2005; 326: 472-4.
88. Lin YL, Lin CY, Chi CW, Huang YT. Study on antifibrotic effects of curcumin in rat hepatic stellate cells. Phytother Res 2009; 23: 927-32.
89. Tang Y, Chen A. Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br J Pharmacol 2010; 161: 1137-49.
90. Yiu WF, Kwan PL, Wong CY, et al. Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase. J Food Sci 2011; 76: H80-9.
91. Shin HS, Han JM, Kim HG, et al. Anti-Atherosclerosis and hyperlipidemia effects of herbal mixture, Artemisia iwayomogi Kitamura and Curcuma longa Linne, in apolipoprotein E-deficient mice. J Ethnopharmacol 2014; 153: 145-50.
92. Kim M, Kim Y. Hypocholesterolemic effects of curcumin via upregulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Practice 2010; 4: 191-5.
93. Kang OH, Kim SB, Seo YS, et al. Curcumin decreases oleic acidinduced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. Eur Rev Med Pharmacol Sci 2013; 17: 2578-86.
94. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates dietinduced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2013; 113: 152-7.
95. Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 2007; 18: 113-9.
96. Na LX, Li Y, Pan HZ, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 2013; 57: 1569-77.
97. DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 2012; 11: 79.
98. Mohamed GA, Ibrahim SR, Elkhayat ES, El Dine RS. Natural antiobesity agents. Bull Facult Pharm 2014; 52: 269-284.
99. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
100. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
101. Tendler D, Lin S, Yancy WS, Jr., et al. The effect of a lowcarbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52: 589-93.
102. Bradford PG. Curcumin and obesity. Biofactors 2013; 39: 78-87.
103. Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010; 68: 729-38.
104. Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 2010; 61: 247-52.
105. Tang Y, Chen A. Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology 2010; 151: 4168-77.
106. Kuo JJ, Chang HH, Tsai TH, Lee TY. Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis. Int J Mol Med 2012; 30: 673-9.
107. [107] Seo KI, Choi MS, Jung UJ, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52: 995-1004.
108. El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SFI, Ahmed AF. The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids. Food Chem Toxicol 2011; 49: 1129-40.
109. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Rev 2002; 23: 201-29.
110. Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005; 36: 232-40.
111. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343.
112. Panzhinskiy E, Hua Y, Lapchak PA, et al. Novel curcumin derivative CNB-001 mitigates obesity-Associated insulin resistances. J Pharmacol Exp Ther 2014; 349: 248-57.
113. [113] Shao W, Yu Z, Chiang Y, et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PloS One 2012; 7: e28784.
114. Li JM, Li YC, Kong LD, Hu QH. Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. Hepatology 2010; 51: 1555-66.
115. Pillarisetti S, Saxena U. Role of oxidative stress and inflammation in the origin of Type 2 diabetes-a paradigm shift. Expert Opin Therap Targets 2004; 8: 401-408.
116. Moller D, Berger J. Role of PPARs in the regulation of obesityrelated insulin sensitivity and inflammation. Int J Obesity 2003; 27: S17-S21.
117. Shehzad A, Ha T, Subhan F, Lee YS. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr 2011; 50: 151-61.
118. Podrini C, Borghesan M, Greco A, Pazienza V, Mazzoccoli G, Vinciguerra M. Redox homeostasis and epigenetics in nonalcoholic fatty liver disease (NAFLD). Curr Pharm Des 2013; 19: 2737-46.
119. Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res 2013; 47: 869-80.
120. Terao K, Niki E. Damage to biological tissues induced by radical initiator 2, 2′-azobis (2-amidinopropane) dihydrochloride and its inhibition by chain-breaking antioxidants. J Free Radic Biol Med 1986; 2: 193-201.
121. Shimasaki H, Saypil W-H, Ueta N. Free radical-induced liver injury. II. Effects of intraperitoneally administered 2, 2’-azobis (2-amidinopropane) dihydrochloride on the fatty acid profiles of hepatic triacylglycerol and phospholipids. Free Radic Res 1991; 14: 247-52.
122. [122] Morita M, Ishida N, Uchiyama K, et al. Fatty liver induced by free radicals and lipid peroxidation. Free Radic Res 2012; 46: 758-65.
123. Vera-Ramirez L, Perez-Lopez P, Varela-Lopez A, Ramirez-Tortosa M, Battino M, Quiles JL. Curcumin and liver disease. BioFactors 2013; 39: 88-100.
124. Mouzaoui S, Rahim I, Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol 2012; 12: 302-11.
125. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Ann Rev Nutr 2010; 30: 173.
126. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Suyasunanont D, Klaikeaw N. Curcumin decreased oxidative stress, inhibited nf-k b activation, and improved liver pathology in ethanol-induced liver injury in rats. J Biomed Biotechnol 2009; 2009: 981963.
127. Kaffashi Elahi R. Preventive effects of turmeric (Curcuma longa Linn.) powder on hepatic steatosis in the rats fed with high fat diet. Life Sci J 2012; 9: 5462-8.
128. Scapagnini G, Colombrita C, Amadio M, et al. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxidants Redox Signal 2006; 8: 395-403.
129. Muthumani M, Miltonprabu S. Ameliorative efficacy of tetrahydrocurcumin against arsenic induced oxidative damage, dyslipidemia and hepatic mitochondrial toxicity in rats. Chem-Biol Interact 2015; 235: 95-105.
130. Badria FA, Ibrahim AS, Badria AF, Elmarakby AA. Curcumin attenuates iron accumulation and oxidative stress in the liver and spleen of chronic iron-overloaded rats. PloS One 2015; 10: e0134156.
131. Tokac M, Taner G, Aydin S, et al. Protective effects of curcumin against oxidative stress parameters and DNA damage in the livers and kidneys of rats with biliary obstruction. Food Chem Toxicol 2013; 61: 28-35.
132. Al-Rubaei ZM, Mohammad TU, Ali LK. Effects of local curcumin on oxidative stress and total antioxidant capacity in vivo study. Pak J Biol Sci 2014; 17: 1237-41.
133. Ghosh S, Bhattacharyya S, Rashid K, Sil PC. Curcumin protects rat liver from streptozotocin-induced diabetic pathophysiology by counteracting reactive oxygen species and inhibiting the activation of p53 and MAPKs mediated stress response pathways. Toxicol Rep 2015; 2: 365-76.
134. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoidpiperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr 2015; 34: 1101-8.
135. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl 2016; 13: 209-20.
136. Kaidashev IP. NF-kB activation as a molecular basis of pathological process by metabolic syndrome. Fiziol Zh 2012; 58: 93-101.
137. Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L, Velagic V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13: 4539-50.
138. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-53.
139. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int 2009; 29: 1457-66.
140. Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41: 926-34.
141. Reyes-Gordillo K, Segovia J, Shibayama M, et al. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam Clin Pharmacol 2008; 22: 417-27.
142. Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 2007; 1770: 989-96.
143. Rushworth SA, Ogborne RM, Charalambos CA, O’Connell MA. Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem Biophys Res Commun 2006; 341: 1007-16.
144. Gu Q, Guan H, Shi Q, Zhang Y, Yang H. Curcumin attenuated acute Propionibacterium acnes-induced liver injury through inhibition of HMGB1 expression in mice. Int Immunopharmacol 2015; 24: 159-65.
145. Na LX, Yan BL, Jiang S, Cui HL, Li Y, Sun CH. Curcuminoids target decreasing serum adipocyte-fatty acid binding protein levels in their glucose-lowering effect in patients with type 2 diabetes. Biomed Environ Sci 2014; 27: 902-6.
146. Wan XH, Li YW, Luo XP. Curcumin attenuated the lipid peroxidation and apoptotic liver injury in copper-overloaded rats. Zhonghua Er Ke Za Zhi 2007; 45: 604-8.
147. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 2013; 169: 1672-92.
148. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-7.
149. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-40.
150. Mantena S, Vaughn D, Andringa K, et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009; 417: 183-93.
151. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006; 12: 555-8.
152. Kuo JJ, Chang HH, Tsai TH, Lee TY. Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis. Int J Mol Med 2012; 30: 643-9.
153. Soto-Urquieta MG, Lopez-Briones S, Perez-Vazquez V, Saavedra-Molina A, Gonzalez-Hernandez GA, Ramirez-Emiliano J. Curcumin restores mitochondrial functions and decreases lipid peroxidation in liver and kidneys of diabetic db/db mice. Biol Res 2014; 47: 74.
154. Rastogi M, Ojha RP, Rajamanickam G, Agrawal A, Aggarwal A, Dubey G. Curcuminoids modulates oxidative damage and mitochondrial dysfunction in diabetic rat brain. Free Radic Res 2008; 42: 999-1005.
155. [155] Panzhinskiy E, Hua Y, Lapchak PA, et al. Novel curcumin derivative CNB-001 mitigates obesity-associated insulin resistance. J Pharmacol Exp Ther 2014; 349: 248-57.
156. Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med 2009; 47: 924-31.
157. Friedman SL. Liver fibrosis--from bench to bedside. J Hepatol 2003; 38 (Suppl 1): S38-53.
158. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 1999; 31: 1120-30.
159. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
160. Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARgamma activity and attenuating oxidative stress. Br J Pharmacol 2012; 166: 2212-27.
161. Chen N, Geng Q, Zheng J, He S, Huo X, Sun X. Suppression of the TGF-beta/Smad signaling pathway and inhibition of hepatic stellate cell proliferation play a role in the hepatoprotective effects of curcumin against alcohol-induced hepatic fibrosis. Int J Mol Med 2014; 34: 1110-6.
162. Pungcharoenkul K, Thongnopnua P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res 2011; 25: 1721-6.
163. Zhai X, Qiao H, Guan W, et al. Curcumin regulates peroxisome proliferator-activated receptor-γ coactivator-1α expression by AMPK pathway in hepatic stellate cells in vitro. Eur J Pharmacol 2015; 746: 56-62.
164. Lin J, Zheng S, Chen A. Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab Invest 2009; 89: 1397-409.
165. Barta A, Janega P, Babal P, Murar E, Cebova M, Pechanova O. The effect of curcumin on liver fibrosis in the rat model of microsurgical cholestasis. Food Funct 2015; 6: 2187-93.
166. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39: 283-99.
167. Tu CT, Yao QY, Xu BL, Wang JY, Zhou CH, Zhang SC. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: Modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. Food Chem Toxicol 2012; 50: 3343-51.
168. Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008; 73: 399-409.
169. Shin SK, Ha TY, McGregor RA, Choi MS. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 2011; 55: 1829-40.
170. Lin J, Chen A. Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2. Mol Cell Endocrinol 2011; 333: 160-71.
171. He Y, Zhu J, Huang Y, Gao H, Zhao Y. Advanced glycation end product (AGE)-induced hepatic stellate cell activation via autophagy contributes to hepatitis C-related fibrosis. Acta Diabetol 2015; 52: 959-69.
172. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-9.
173. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-9.
174. Diehl AM. Lessons from animal models of NASH. Hepatology Res 2005; 33: 138-44.
175. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-13.
176. Tang Y, Zheng S, Chen A. Curcumin eliminates leptin’s effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 2009; 150: 3011-20.
177. Tang Y, Chen A. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest 2014; 94: 503-16.
178. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014; 46: 2-18.
179. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 183-9.
180. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894-900.
181. Lao CD, Ruffin MTT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
182. [182] Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
183. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 1411-7.
184. Liu W, Zhai Y, Heng X, et al. Oral bioavailability of curcumin: problems and advancements. J Drug Target 2016; 24: 694-702.
185. Adhvaryu MR, Reddy N, Vakharia BC. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol 2008; 14: 4753-62.
186. Irving GR, Iwuji CO, Morgan B, et al. Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials 2015; 16: 110.
187. Bortel N, Armeanu-Ebinger S, Schmid E, et al. Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB-and the beta-catenin pathways. Oncotarget 2015; 6: 40680-91.
188. [188] Wang Y, Li J, Zhuge L, Su D, Yang M, Tao S. Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine-and choline-deficient diet. Exp Ther Med 2014; 7: 663-8.
189. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014; 232: 40-51.
190. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates dietinduced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2013; 113: 152-7.
191. [191] Vizzutti F, Provenzano A, Galastri S, et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 2010; 90: 104-15.
192. Zhao SG, Li Q, Liu ZX, et al. Curcumin attenuates insulin resistance in hepatocytes by inducing Nrf2 nuclear translocation. Hepato-Gastroenterology 2010; 58: 2106-11.
193. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003; 92: 33-8.
194. Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000; 28: 1303-12.
195. Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010; 15: 337-44.
196. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008; 149: 3549-58.
197. Karimian MS, Pirro M, Majeed M, Sahebkar A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev 2016; 33: 55-63.
198. Kang Q, Chen A. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Invest 2009; 89: 1275-90.
199. Kang Q, Chen A. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDLinduced activation of hepatic stellate cells. Br J Pharmacol 2009; 157: 1354-67.
200. [200] Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol 2012; 166: 2212-27.
201. Jang E-M, Choi M-S, Jung UJ, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat–fed hamsters. Metabolism 2008; 57: 1576-83.
202. Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-α. Free Radic Biol Med 2009; 47: 924-31.
203. Na LX, Zhang YL, Li Y, et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr, Metabol Cardiovasc Dis 2011; 21: 526-33.
204. Kuroda M, Mimaki Y, Nishiyama T, et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KKAy mice. Biol Pharm Bull 2005; 28: 937-9.
205. Kuo J-J, Chang H-H, Tsai T-H, Lee T-Y. Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis. Int J Mol Med 2012; 30: 673-9.
206. Panahi Y, Kianpour P, Mohtashami R, et al. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol 2016; 68: 223-9.
207. Rahmani S, Asgary S, Askari G, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res 2016; 30: 1540-8.